JianPi-QingHua formula attenuates nonalcoholic fatty liver disease by regulating the AMPK/SIRT1/NF-κB pathway in high-fat-diet-fed C57BL/6 mice

References

• Buzzetti E, Pinzani M, Tsochatzis EA. 2016. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 65(8):1038–1048.
   PubMed Web of Science ®Google Scholar
• Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 11:183–190.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang Y, Graham S, Wang X, Cai D, Huang M, Pique-Regi R, Dong XC, Chen YE, Willer C, et al. 2020. Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping. J Hepatol. 73(2):263–276.
   PubMed Web of Science ®Google Scholar
• Cui J, Shi Y, Xu X, Zhao F, Zhang J, Wei B. 2021. Identifying the cardioprotective mechanism of Danyu Tongmai granules against myocardial infarction by targeted metabolomics combined with network pharmacology. Phytomedicine. 98:153829.
   PubMed Web of Science ®Google Scholar
• Ding X, Jian T, Li J, Lv H, Tong B, Li J, Meng X, Ren B, Chen J. 2020. κChicoric acid ameliorates nonalcoholic fatty liver disease via the AMPK/Nrf2/NFB signaling pathway and restores gut microbiota in high-fat-diet-fed mice. Oxid Med Cell Longev. 2020:9734560.
   PubMed Web of Science ®Google Scholar
• Duan XY, Qiao L, Fan JG. 2012. Clinical features of nonalcoholic fatty liver disease-associated hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 11(1):18–27.
   PubMed Web of Science ®Google Scholar
• Fujii H, Kawada N. 2020. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease. Int J Mol Sci. 21:3863.
   PubMed Web of Science ®Google Scholar
• Garcia D, Hellberg K, Chaix A, Wallace M, Herzig S, Badur MG, Lin T, Shokhirev MN, Pinto AFM, Ross DS, et al. 2019. Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD. Cell Rep. 26(1):192–208.
   PubMed Web of Science ®Google Scholar
• Gong F, Chen QG, Han X, Liu YH, Lu H. 2020. Effects of Jianpi Qinghua formula on glycolipid metabolism indexes and body mass in patients of type 2 diabetes mellitus with syndrome of deficiency of both qi and yin. Shanghai J Traditional Chinese Med. 54(S1):65–6676.
   Google Scholar
• Grossini E, Garhwal DP, Calamita G, Romito R, Rigamonti C, Minisini R, Smirne C, Surico D, Bellan M, Pirisi M. 2021. Exposure to plasma from non-alcoholic fatty liver disease patients affects hepatocyte viability, generates mitochondrial dysfunction, and modulates pathways involved in fat accumulation and inflammation. Front Med. 8:693997.
   Web of Science ®Google Scholar
• Han R, Qiu H, Zhong J, Zheng N, Li B, Hong Y, Ma J, Wu G, Chen L, Sheng L. 2021. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota. Phytomedicine. 85:153544.
   PubMed Web of Science ®Google Scholar
• Heida A, Gruben N, Catrysse L, Koehorst M, Koster M, Kloosterhuis NJ, Gerding A, Havinga R, Bloks VW, Bongiovanni L, et al. 2021. The hepatocyte IKK: NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis. Mol Metab. 54:101349.
   PubMed Web of Science ®Google Scholar
• Hotamisligil GS. 2006. Inflammation and metabolic disorders. Nature. 444(7121):860–867.
   PubMed Web of Science ®Google Scholar
• Jiang G, Chen D, Li W, Liu C, Liu J, Guo Y. 2020. Effects of wogonoside on the inflammatory response and oxidative stress in mice with nonalcoholic fatty liver disease. Pharm Biol. 58:1177–1183.
   PubMed Web of Science ®Google Scholar
• Kashyap ML, Ganji S, Nakra NK, Kamanna VS. 2019. Niacin for treatment of nonalcoholic fatty liver disease (NAFLD): novel use for an old drug? J Clin Lipidol. 13(6):873–879.
   PubMed Web of Science ®Google Scholar
• Li S, Qian Q, Ying N, Lai J, Feng L, Zheng S, Jiang F, Song Q, Chai H, Dou X. 2020. Activation of the AMPK-SIRT1 pathway contributes to protective effects of salvianolic acid A against lipotoxicity in hepatocytes and NAFLD in mice. Front Pharmacol. 11:560905.
   PubMed Web of Science ®Google Scholar
• Liu J, Yuan Y, Gong X, Zhang L, Zhou Q, Wu S, Zhang X, Hu J, Kuang G, Yin X, et al. 2020. Baicalin and its nanoliposomes ameliorates nonalcoholic fatty liver disease via suppression of TLR4 signaling cascade in mice. Int Immunopharmacol. 80:106208.
   PubMed Web of Science ®Google Scholar
• Liu YH, Han X, Cai MJ, Jin SY, Yan ZH, Lu H, Chen QG. 2022. Jianpi Qinghua fomula alleviates insulin resistance via restraining of MAPK pathway to suppress inflammation of the small intestine in DIO mice. BMC Complement Med Ther. 22:129.
   PubMedGoogle Scholar
• Liu YH, Qiu Y, Chen QG, Han X, Cai MJ, Hao L. 2021. Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K/Akt signaling pathway in diabetic rats and HepG cells. Biomed Pharmacother. 137:111325.
   PubMed Web of Science ®Google Scholar
• Nelson JE, Wilson L, Brunt EM, Yeh MM, Kleiner DE, Unalp-Arida A, Kowdley KV, Nonalcoholic Steatohepatitis Clinical Research Network. 2011. Relationship between the pattern of hepatic iron deposition and histological severity in nonalcoholic fatty liver disease. Hepatology. 53(2):448–457.
   PubMed Web of Science ®Google Scholar
• Peixoto CA, de Oliveira WH, da Araújo SMR, Nunes AKS. 2017. AMPK activation: role in the signaling pathways of neuroinflammation and neurodegeneration. Exp Neurol. 298:31–41.
   PubMed Web of Science ®Google Scholar
• Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschöp MH. 2008. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 105(28):9793–9798.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Kountouras J, Mantzoros CS. 2019. Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics. Metabolism. 92:82–97.
   PubMed Web of Science ®Google Scholar
• Powell EE, Wong VW, Rinella M. 2021. Non-alcoholic fatty liver disease. Lancet. 397(10290):2212–2224.
   PubMed Web of Science ®Google Scholar
• Rohm TV, Meier DT, Olefsky JM, Donath MY. 2022. Inflammation in obesity, diabetes, and related disorders. Immunity. 55:31–55.
   PubMed Web of Science ®Google Scholar
• Santhekadur PK, Kumar DP, Sanyal AJ. 2018. Preclinical models of non-alcoholic fatty liver disease. J Hepatol. 68(2):230–237.
   PubMed Web of Science ®Google Scholar
• Smith BK, Marcinko K, Desjardins EM, Lally JS, Ford RJ, Steinberg GR. 2016. Treatment of nonalcoholic fatty liver disease: role of AMPK. Am J Physiol Endocrinol Metab. 311(4):E730–E740.
   PubMed Web of Science ®Google Scholar
• Song YM, Lee YH, Kim JW, Ham DS, Kang ES, Cha BS, Lee HC, Lee BW. 2015. Metformin alleviates hepatosteatosis by restoring SIRT1-mediated autophagy induction via an AMP-activated protein kinase-independent pathway. Autophagy. 11(1):46–59.
   PubMed Web of Science ®Google Scholar
• Tang K, Deng Y, Zheng C, Nie H, Pan M, Chen R, Xie J, Yang Q, Zhang Y. 2020. Prevention of nonalcoholic hepatic steatosis by Shenling Baizhu powder: involvement of adiponectin-induced inhibition of hepatic SREBP-1c. Oxid Med Cell Longev. 2020:9701285.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. 2010. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 52:1836–1846.
   PubMed Web of Science ®Google Scholar
• Xu H, Lyu X, Guo X, Yang H, Duan L, Zhu H, Pan H, Gong F, Wang L. 2022. Distinct AMPK-mediated FAS/HSL pathway is implicated in the alleviating effect of nuciferine on obesity and hepatic steatosis in HFD-fed mice. Nutrients. 14:1898.
   PubMed Web of Science ®Google Scholar
• Xu JH, Chen QG, Han X, Liu YH, Jin SY, Cai MJ, Liu SY, Lu H. 2021. Elucidation of the mechanisms and molecular targets of Jianpi Qinghua formula for treating insulin resistance in type 2 diabetes based on network pharmacology. Liaoning J Trad Chinese Med. 48:5-9 + 253–254.
   Google Scholar
• Yan J, Yao B, Kuang H, Yang X, Huang Q, Hong T, Li Y, Dou J, Yang W, Qin G, et al. 2019. Liraglutide, sitagliptin, and insulin glargine added to metformin: The effect on body Weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology. 69(6):2414–2426.
   PubMed Web of Science ®Google Scholar
• Zamani-Garmsiri F, Hashemnia SMR, Shabani M, Bagherieh M, Emamgholipour S, Meshkani R. 2021. Combination of metformin and genistein alleviates non-alcoholic fatty liver disease in high-fat diet-fed mice. J Nutr Biochem. 87:108505.
   PubMed Web of Science ®Google Scholar
• Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H, Xia M, Chang X, Lu Y, Li Y, et al. 2019. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 141:192–204.
   PubMed Web of Science ®Google Scholar